INO - Inovio Pharmaceuticals, Inc.
| Previous Close | 3.3400 |
| Open | 3.3000 |
| Bid | 3.0200 x 3200 |
| Ask | 4.5900 x 1200 |
| Day's Range | 3.2500 - 3.3600 |
| 52 Week Range | 3.0200 - 6.3000 |
| Volume | 651,535 |
| Avg. Volume | 1,213,641 |
| Market Cap | 324.492M |
| Beta (3Y Monthly) | 2.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9970 |
| Earnings Date | May 8, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.75 |
- Zacks•4 days ago
QIAGEN Partners Inovio to Develop Companion Diagnostics
QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.
- Benzinga•4 days ago
The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...
- PR Newswire•5 days ago
Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer
Frankfurt Prime Standard: QIA) today announced a collaboration to co-develop a diagnostic test to identify patients most likely to respond to VGX-3100, Inovio's immunotherapy to treat advanced cervical dysplasia associated with the human papillomavirus virus (HPV). This precision medicine partnership focuses on Inovio's VGX-3100, a late-stage product candidate currently in two pivotal Phase 3 clinical trials (REVEAL 1 and 2) with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus.
- PR Newswire•6 days ago
Inovio and Plumbline Life Sciences Establish Animal Health Collaboration to Develop A Novel Vaccine Against Deadly African Swine Fever Virus
PLYMOUTH MEETING, Pa. and SEOUL, South Korea, May 15, 2019 /PRNewswire/ -- Inovio Pharmaceuticals Inc. (INO) and Plumbline Life Sciences (XKRX:222670) today announced a collaboration to co-develop a novel animal health vaccine for African swine fever (ASF) virus. The vaccine will be developed using Inovio's SynCon® technology and delivered using CELLECTRA® efficacy-enabling devices. Plumbline, based in South Korea, will fund all development and commercialization of the ASF vaccine.
- Zacks•11 days ago
Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates
Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.
- Motley Fool•11 days ago
What You'll Want to Know About Inovio Pharmaceuticals' Q1 Earnings Update
More revenue, more cash, lower expenses, and a lot of pipeline activity were the major stories for the biotech in Q1.
- Thomson Reuters StreetEvents•11 days ago
Edited Transcript of INO earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Inovio Pharmaceuticals Inc Earnings Call
Motley Fool•11 days agoInovio Pharmaceuticals Inc (INO) Q1 2019 Earnings Call Transcript
INO earnings call for the period ending March 31, 2019.
- Zacks•12 days ago
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates
Inovio (INO) delivered earnings and revenue surprises of -3.45% and -36.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•12 days ago
Inovio: 1Q Earnings Snapshot
On a per-share basis, the Plymouth Meeting, Pennsylvania-based company said it had a loss of 30 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- PR Newswire•12 days ago
Inovio Pharmaceuticals Reports 2019 First Quarter Financial Results
PLYMOUTH MEETING, Pa. , May 9, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO), an innovative biotechnology company focused on the discovery, development and commercialization of its synthetic ...
- Simply Wall St.•12 days ago
If You Had Bought Inovio Pharmaceuticals (NASDAQ:INO) Stock Three Years Ago, You'd Be Sitting On A 58% Loss, Today
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Zacks•14 days ago
What's in the Cards for AcelRx (ACRX) This Earnings Season?
We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.
- Zacks•14 days ago
What's in Cards for Cumberland (CPIX) This Earnings Season?
Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.
- PR Newswire•15 days ago
Inovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100
PLYMOUTH MEETING, Pa. , May 6, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that its lead Phase 3 product candidate, VGX-3100, has been granted an Advanced Therapy Medicinal ...
- Zacks•19 days ago
Protalix (PLX) to Report Q1 Earnings: What's in the Cards?
Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.
- Zacks•20 days ago
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire•20 days ago
Inovio Pharmaceuticals to Report First Quarter 2019 Financial Results on May 9, 2019
PLYMOUTH MEETING, Pa., May 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that first quarter 2019 financial results will be released after the market close on May 9, 2019. Following the release, the Company will host a conference call and live webcast at 4:30 p.m. ET, to provide a general business update and financial results for the first quarter 2019. Inovio is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines that transform the treatment and prevention of cancer and infectious disease. Inovio's proprietary technology platform applies antigen sequencing and DNA delivery to activate potent immune responses to targeted diseases. The technology functions exclusively in vivo, and has been demonstrated to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens.
- American City Business Journals•last month
Cover story: Joseph Kim's art of the bio-deal
While many biopharmaceutical companies have partnerships or collaborations with one or two larger companies, Inovio Pharmaceuticals has product development deals in place with more than a half dozen pharmaceutical and biotech firms and research organizations inside and outside the United States. Inovio is in that position largely because it is developing a technology platform with two parts that can be applied to a variety of medical conditions. The second part is the system for delivering the therapy through the skin or into muscle tissues using brief and low voltage electronic pulses. That standing, said Inovio co-founder and CEO J. Joseph Kim, gives the Plymouth Meeting-based company different aspirations than other development-stage drug developers.
- PR Newswire•last month
Inovio Publishes Cancer Killing Data of Its Transformative DNA-encoded Bi-specific T Cell Engagers (dBiTEs™) in a Peer-reviewed Journal
PLYMOUTH MEETING, Pa., April 18, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today the company's novel DNA-encoded Bi-specific T Cell Engagers (dBiTEs) generated potent anti-tumor activities and cleared established tumors in preclinical studies. Inovio's dBiTE results were published in a JCI Insight article entitled, "DNA-encoded bi-specific T cell engagers and antibodies present long-term antitumor activity," by Inovio and its collaborators at The Wistar Institute. JCI Insight is a peer-reviewed journal published by the American Society for Clinical Investigation dedicated to well-executed preclinical and clinical research studies.
- MoneyShow•last month
Inovio- A Biotech Bet for New World Investors
In a recent press release, Inovio (INO) said they completed enrollment three months ahead of schedule in the Phase 1/2, 52-patient trial of INO-5401 for newly-diagnosed glioblastoma, asserts Michael Murphy, growth stock expert and editor of New World Investor.
